10 of the Best Stocks to Buy for 2022
Shares of Pfizer were upgraded to Buy from Neutral at UBS, with the firm writing that it expects antiviral pill Paxlovid to reach sales of at least $14 billion next year, or 40% above Wall Street expectations. UBS analyst Colin Bristow, in a research note Monday, also boosted the price target on the stock to $60 from $52. Pfizer (ticker: PFE) shares rose 2.5% to $54.10. Bristow wrote how Pfizer’s Covid franchise — Paxlovid and Cominarty, the company’s Covid-19 vaccine — has peak sales potential in 2022 of $50 billion.